[go: up one dir, main page]

NO20082922L - Terapeutisk middel for keratokonjunktive lidelser - Google Patents

Terapeutisk middel for keratokonjunktive lidelser

Info

Publication number
NO20082922L
NO20082922L NO20082922A NO20082922A NO20082922L NO 20082922 L NO20082922 L NO 20082922L NO 20082922 A NO20082922 A NO 20082922A NO 20082922 A NO20082922 A NO 20082922A NO 20082922 L NO20082922 L NO 20082922L
Authority
NO
Norway
Prior art keywords
therapeutic agent
defect
corneal
eprosartan
salt
Prior art date
Application number
NO20082922A
Other languages
English (en)
Norwegian (no)
Inventor
Masatsugu Nakamura
Keiichi Shibagaki
Shin-Ichiro Hirai
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of NO20082922L publication Critical patent/NO20082922L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20082922A 2005-12-06 2008-06-25 Terapeutisk middel for keratokonjunktive lidelser NO20082922L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005351712 2005-12-06
PCT/JP2006/324324 WO2007066678A1 (ja) 2005-12-06 2006-12-06 角結膜障害治療剤

Publications (1)

Publication Number Publication Date
NO20082922L true NO20082922L (no) 2008-06-27

Family

ID=38122824

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082922A NO20082922L (no) 2005-12-06 2008-06-25 Terapeutisk middel for keratokonjunktive lidelser

Country Status (8)

Country Link
US (1) US20090270474A1 (ja)
EP (1) EP1958949A4 (ja)
KR (1) KR20080074128A (ja)
CN (1) CN101312962A (ja)
CA (1) CA2631231A1 (ja)
NO (1) NO20082922L (ja)
RU (1) RU2423127C2 (ja)
WO (1) WO2007066678A1 (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD4412C1 (ro) * 2014-08-29 2016-11-30 Алёна ДУРНЯ Utilizare a acidului 4-({2-butil-5-[2-carboxi-2-(tiofen-2-ilmetil)et-1-en-1-il] -1H-imidazol-1-il}metil) benzoic pentru ameliorarea elasticităţii vasculare în profilaxia complicaţiilor de geneză hipertensivă
WO2023034779A1 (en) * 2021-08-31 2023-03-09 The Cleveland Clinic Foundation Topical drug treatment to prevent or reduce corneal scarring

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185351A (en) * 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
DK0634175T3 (da) * 1993-07-15 2001-04-30 Hoffmann La Roche Farmaceutisk kombination, der indeholder en hæmmer af renin-angiotensin-systemet og en endothelin-antagonist
JP3136352B2 (ja) * 1996-01-22 2001-02-19 参天製薬株式会社 角結膜疾患治療剤
US6420412B2 (en) * 1996-03-29 2002-07-16 Smithkline Beecham Corporation Eprosartan dihydate and a process for its production and formulation
JPH10218792A (ja) * 1997-02-12 1998-08-18 Santen Pharmaceut Co Ltd アンギオテンシン変換酵素阻害薬を有効成分とする涙液分泌促進および角結膜障害治療剤
EP0991647B1 (en) * 1997-06-27 2002-09-04 Smithkline Beecham Corporation Eprosartan monohydrate
HU226948B1 (en) * 1999-04-28 2010-03-29 Takeda Pharmaceutical Use of angiotensin ii antagonist for prevention or therapy of progression of simplex retinopathy or preproliferating retinopathy
JP2001031636A (ja) * 1999-05-18 2001-02-06 Senju Pharmaceut Co Ltd α−ケトアミド誘導体およびその医薬用途
JP2001058958A (ja) * 1999-08-20 2001-03-06 Senju Pharmaceut Co Ltd 涙液分泌促進剤
US20030018044A1 (en) * 2000-02-18 2003-01-23 Peyman Gholam A. Treatment of ocular disease
FI114483B (fi) * 2001-02-20 2004-10-29 Jurilab Ltd Oy Menetelmä kohonneen verenpaineen riskin osoittamiseksi ja sen käytöt

Also Published As

Publication number Publication date
RU2423127C2 (ru) 2011-07-10
EP1958949A4 (en) 2010-04-28
CN101312962A (zh) 2008-11-26
US20090270474A1 (en) 2009-10-29
RU2008127378A (ru) 2010-01-20
WO2007066678A1 (ja) 2007-06-14
CA2631231A1 (en) 2007-06-14
EP1958949A1 (en) 2008-08-20
KR20080074128A (ko) 2008-08-12

Similar Documents

Publication Publication Date Title
NO20076398L (no) Preventivt eller terapeutisk middel for keratokonjunktive forstyrrelser
DE602004030470D1 (de) Therapeutisches mittel für keratokonjunktive erkrankungen
NO2020010I1 (no) fostamatinib eller et farmasøytisk akseptabelt salt av fostamatinib, eller et hydrat, solvat eller N-oksid av fostamatinib eller det farmasøytisk akseptable saltet av fostamatinib, spesielt fostamatinib dinatrium, eventuelt på form av et hydrat
PE20070241A1 (es) Sales de 4-metil-n-[3-(4-metil-imidazo-1-lil)-5-triflurometil-fenil]-3-(4-piridi-3-nil-pirimidi-2-nilamino)-benzamida
CY1118007T1 (el) Μεθοδοι για την χορηγηση υπογλυκαιμικων μεσων
PE20110598A1 (es) Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38
NO20083568L (no) Hydantoinforbindelser for behandling av inflammatoriske forstyrrelser
DK1924264T3 (da) Diaminopyrimidiner som p2x3- og p2x2/3-modulatorer
NO20082481L (no) Nye 2-aminoheterosykluser som er nyttige ved behandling av ABETA-relaterte patologier
NO20081550L (no) Preventivt eller terapeutisk middel for sykdom forarsaket av minskning i lakrimalvaeske
CR9365A (es) Compuestos y metodos para la inhibicion de la protein-cinasa raf
NO20076691L (no) Nanopartikulaere imatinib-mesylatformuleringer
NO20076450L (no) Heterosykliske forbindelser som nikotinsyrereseptoragonister for behandling av dyslipidemi
PE20061366A1 (es) Compuestos y composiciones como inhibidores de quinasa de proteina
EA200870019A1 (ru) Лактамовые соединения и способы их применения
PE20090244A1 (es) Inhibidores de la proteina activadora de la 5-lipoxigenasa (flap)
NO20076502L (no) Pyrrolopyridiner nyttige som inhibitorer av proteinkinase
NO20082674L (no) Heterocykliske modulatorer for ATP-bindende kassett-transportere
NO20082476L (no) Bicykliske forbindelser med kinaseinhiberende aktivitet
EA200601223A1 (ru) Производные сульфонамида для лечения заболеваний
NO20090910L (no) Sulfonamid-derivater som adrenerge agonister og muskariniske antagonister
DE602006021776D1 (de) Als kinaseinhibitoren geeignete aminopyrimidine
CL2007000789A1 (es) Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
NO20076460L (no) Nye fluorenderivater, sammensetninger inneholdende nevnte derivater og anvendelse derav
EA200800201A1 (ru) Кристаллические формы 4-метил-n-[3-(4-метилимидазол-1-ил)-5-трифторметилфенил]-3-(4-пиридин-3-илпиримидин-2-иламино)бензамида

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application